Exclusive US rights to ALA-002 give the longevity-focused biotech a second clinical program as interest in brain health accelerates.
Longevity has largely been a story about cells. Investors have chased therapies that clear out senescent cells, protect telomeres or reprogram aging tissues back to a younger state. But what if one of aging’s biggest drivers isn’t found in the body first – it’s found in the brain?
Researchers have long known that chronic stress, trauma and depression don’t just affect mental health; they leave measurable marks across the body, from inflammation to cardiovascular health and even biological aging. That raises an intriguing – if still unanswered – question: if future therapies can help the brain form healthier connections and recover from trauma, could they also influence how we age?
It’s a question that sits quietly beneath Jupiter Neurosciences’ latest move. The Nasdaq-listed biotech has signed a definitive agreement with PharmAla Biotech Holdings for the perpetual exclusive US rights to ALA-002, a clinical-stage psychedelic therapy candidate, in a deal worth up to $100 million [1]. Look closer, it hints at the possibility that longevity medicine is beginning to redefine itself.
Because Jupiter is no longer building around one idea. It now spans a consumer longevity supplement with Nugevia, a resveratrol-based therapy for Parkinson’s disease through JOTROL, and now an investigational psychedelic medicine designed for neuropsychiatric disorders. Together, those assets begin to sketch something that doesn’t fit neatly into today’s categories – a portfolio focused less on lifespan alone and more on what some investors may eventually think of as ‘brain span’.
From inflammation to neural rewiring
The science behind Jupiter’s pipeline targets different problems, but they all converge on one organ. JOTROL is being studied for Parkinson’s disease and is designed to improve delivery of resveratrol, a naturally occurring compound that researchers have investigated for its potential role in reducing inflammation inside the nervous system.
ALA-002 approaches the problem from an entirely different angle. Rather than trying to calm inflammation, it is being developed to help patients with conditions such as treatment-resistant PTSD and severe anxiety through MDMA-assisted psychotherapy. Put simply, if inflammation is like static interfering with the brain’s communication network, therapies such as ALA-002 aim to help the brain build healthier communication pathways altogether.
Whether those two approaches could ever complement one another remains entirely hypothetical. Jupiter has made no claims that combining them would produce additional benefits, nor have clinical studies demonstrated such an effect. But the fact that one company now owns assets targeting both neuroinflammation and neural plasticity illustrates how neuroscience and longevity are broadening their scope beyond traditional anti-aging biology.
The agreement transforms Jupiter from a company with a single clinical-stage program into one with two.
ALA-002 is a patented investigational version of MDMA that has received the FDA’s Novel Chemical Entity designation, providing regulatory protection if ultimately approved. The company believes the candidate offers improved cardiovascular safety and lower abuse potential while preserving the therapeutic characteristics researchers are studying in MDMA-assisted psychotherapy.
Just as important as the science is the timing. Earlier this year, President Donald J. Trump signed an Executive Order intended to accelerate investigational psychedelic therapies for serious mental illness, including measures aimed at speeding regulatory review and expanding patient access. While no policy guarantees regulatory approval, the direction of travel is difficult to ignore. Psychedelic medicine is increasingly moving from the margins of biotech into serious conversations among regulators, investors and healthcare providers.
Against that backdrop, Jupiter’s acquisition looks less like a gamble on a single asset and more like a strategic positioning exercise.
“This agreement significantly expands our CNS strategy by adding a differentiated clinical-stage asset that complements our Parkinson’s disease program. We believe ALA-002 addresses a large unmet medical need and provides Jupiter with a second independent development opportunity,” said Christer Rosén, Chairman and CEO of Jupiter Neurosciences. “Our focus is now disciplined clinical execution, prudent capital allocation and advancing both programs toward meaningful value-creating milestones, while recognizing the inherent risks of clinical development.”
President and Chief Business Officer Alison Silva believes the company is entering a defining period.
“This agreement broadens our strategic reach in CNS and brain plasticity while strengthening our shareholders’ equity and establishing a clear path to build long-term value through disciplined clinical and regulatory execution in the United States. We’ve spent the past few months aligning strategy and mobilizing for execution in the space of psychedelic medicines, exemplified by the two new experts we have brought onto our Board of Directors. Drs Tomas Philipson and Andrew Cutler. The next 12 months will be transformative for Jupiter,” he said.
PharmAla’s Founding CEO, Nicholas Kadysh, explained that the company developed ALA-002 to offer a significantly improved, safer MDMA-based therapeutic option for patients suffering from various neuropsychiatric disorders. He noted that while PharmAla plans to continue advancing the candidate internationally, partnering with Jupiter is a strong strategic fit for both organizations due to Jupiter’s dedicated focus on CNS disorders and its commitment to bringing innovative brain therapies to the United States.
The longevity industry has spent much of the past decade asking how to make cells younger. Increasingly, it is asking a different question: what happens if we make the brain healthier? Cognitive resilience, emotional wellbeing and protection against neurodegenerative disease are becoming central to conversations about healthspan. Living longer means little if those extra years are spent battling neurological decline or untreated mental illness.
ALA-002 remains an investigational therapy with significant clinical and regulatory hurdles ahead. Yet Jupiter’s latest move reflects a broader shift in where longevity capital is flowing. The companies attracting attention today are not simply trying to slow aging at the cellular level; they are beginning to ask how the brain shapes the aging process itself.
If that thinking continues to gain momentum, longevity investing may soon expand beyond molecules that target aging biology alone. The next generation of companies could be those that recognize one simple idea: extending healthspan may start not just with healthier cells, but with healthier minds.
